A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. In ...
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study This randomized, parallel-group, phase II study ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s ...
We conducted an unblinded, two-arm, parallel randomized controlled trial at two sites among patients starting radiotherapy or chemotherapy. The intervention group completed the DT&PL, rating distress ...
News-Medical.Net on MSN
Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
By Hugo Francisco de Souza Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial ...
Objective To determine whether liquefied petroleum gas (LPG) can reduce perinatal mortality in a setting with high reliance on biomass fuels for cooking.Design Community-based two-arm parallel cluster ...
Glutamine is thought to have beneficial effects on the metabolic and stress response to severe injury. Clinical trials involving patients with burns and other critically ill patients have shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results